Heidari Parnaz, Heidari Behzad, Babaei Mansour
Sina Clinic Hospital, Babol, Iran.
Mobility Impairment Research Center, Babol University of Medical Sciences, Iran.
Reumatologia. 2020;58(6):424-435. doi: 10.5114/reum.2020.102008. Epub 2020 Dec 23.
In knee osteoarthritis (KOA), synovial inflammation is linked with pain, swelling and structural abnormalities. Intra-articular corticosteroids (IACS) have been considered for pain relief in subjects who are non-responders to standard therapy. However, the results vary across different studies. This review aims to determine efficacy of IACS in KOA by review of the existing data. In several randomized controlled trials (RCTs), meta-analyses and uncontrolled studies a single IACS resulted in pain relief from 1 to a few weeks. In a few studies repeated IACS every three months provided a longer duration of pain relief and functional improvement in a proportion of patients. Baseline synovitis was predictor of treatment response in some but not all studies. Based upon the existing data, IACS provides a short-term pain relief in a proportion of patients. Given, anti-inflammatory properties of IACS, it is likely to be more effective in subgroups of KOA who display inflammatory phenotype.
在膝关节骨关节炎(KOA)中,滑膜炎症与疼痛、肿胀及结构异常相关。对于对标准治疗无反应的患者,关节内注射皮质类固醇(IACS)被视为缓解疼痛的方法。然而,不同研究的结果各异。本综述旨在通过回顾现有数据来确定IACS在KOA中的疗效。在多项随机对照试验(RCT)、荟萃分析及非对照研究中,单次注射IACS可在1至数周内缓解疼痛。在一些研究中,每三个月重复注射IACS可使部分患者获得更长时间的疼痛缓解及功能改善。在部分但并非所有研究中,基线滑膜炎是治疗反应的预测指标。基于现有数据,IACS可使部分患者获得短期疼痛缓解。鉴于IACS的抗炎特性,其可能在表现出炎症表型的KOA亚组中更有效。